<DOC>
	<DOCNO>NCT02722837</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability treatment sofosbuvir ( SOF ) /velpatasvir ( VEL ; GS-5816 ) fix dose combination ( FDC ) 12 week participant chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed Dose Combination 12 Weeks Participants With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key HCV RNA ≥ 10^4 IU/mL screen Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy Key Any chronic liver disease Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Clinical hepatic decompensation Prior exposure SOF nucleotide analogue HCV NS5B inhibitor HCV NS5A inhibitor NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>